Advertisement

HindustanTimes Thu,02 Oct 2014

Sun Pharma Q3 net up 32%

HT Correspondent, Hindustan Times  Mumbai, February 08, 2013
First Published: 21:18 IST(8/2/2013) | Last Updated: 21:20 IST(8/2/2013)

Sun Pharmaceutical Inds on Friday announced a 32% year-on-year growth in consolidated net profit to Rs. 881.30 crore for the quarter ended December from Rs. 668.30 crore in the same period a year ago, driven by strong sales in the United States market.

Advertisement

Sales of branded prescription formulations in US rose 44% to Rs. 1,495 crore from Rs. 1,040 crore in the same quarter previous year. The US sales accounted for 52% of total sales during the quarter.

"All our businesses continue to perform in-line with our expectations. The acquisition of DUSA and URL's generic business will further strengthen our presence in the US," said Dilip Shanghvi, MD, Sun Pharmaceutical.

US-based Dusa, a dermatology company, was acquired by Sun pharma for around R1,250 crore last year. Caraco Pharma, Sun Pharma's wholly-owned subsidiary, also announced the acquisition of URL Pharma Inc's generic business in US, during the quarter.


Advertisement
more from Business

Vijay Mallya has to clear loan defaults to serve as USL chairman: Diageo

Loan default cases against Vijay Mallya and his UB Group may cast a shadow over his continuation as chairman of United Spirits Ltd in the future, with its current parent, UK-based Diageo, making it clear in a statement from its headquarters in London.

markets
Advertisement
Most Popular
Advertisement
Advertisement
Copyright © 2014 HT Media Limited. All Rights Reserved